Cure8 research brief
Identifying baseline cellular states that predict disease course or response to anti‑TNF could help researchers develop predictive biomarkers and new therapeutic strategies for pediatric Crohn’s disease.
Pediatric IBD researchers and clinicians, researchers using single‑cell sequencing or immune‑profiling, and families of children newly diagnosed with Crohn’s disease interested in biomarker research.
The researchers profiled >200,000 single‑cell transcriptomes from treatment‑naive pediatric Crohn’s biopsies, repeat biopsies after anti‑TNF therapy, and non‑inflamed pediatric controls. They developed an analysis pipeline (ARBOL) to define high‑resolution epithelial, stromal, and immune cell states.
They report a pediCD cellular ecosystem (pediCD‑TIME) — a vector of T cell, innate lymphoid, myeloid, and epithelial states — that stratifies patients by severity and anti‑TNF response, and they observe that anti‑TNF treatment shifts the pediatric tissue ecosystem toward an adult, more treatment‑refractory state.
The study is grounded in the article abstract from eLife and summarizes the authors' reported methods and claims without adding new data or clinical recommendations.
This classification and brief are based on the article abstract (structured content depth: abstract). The study is a high‑resolution, mechanistic/basic science investigation; it does not by itself provide clinical recommendations or validated predictive tests.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: HZ, BD, KK co-inventor on a provisional patent application relating to methods of stratifying and treating IBD. US Patent US20240150453A1, AY, VT, VN, KC, RF, BB, KB, LC, CM, PK, AA, MS, Jd, Rv, AK, CK, FT, MF, DL, GD, XD, LC, VM No competing interests declared, NF, BK, SC, SJ, YY, MD, MW, SH, GK, AH, WL, SH, YW employee and shareholder of Regeneron Pharmaceuticals, Inc, LA consultant for Takeda Pharmaceuticals, DS co-founder, CM, president of NiMBAL Health, SS scientific advisory board participation for Pfizer, Lilly, IFM therapeutics, Merck, Pandion, and Takeda Inc, and grant support from Pfizer, Novartis, Amgen, Takeda Consulting for Hoffman La Roche and Amgen, GW research funding from Abbvie, Jansen, Takeda, Allakos; SAB for Abbvie, Bristol Myers Squibb; DSMB for Abbvie, AS compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Hovione, Third Rock Ventures, OchreBio, FL82, Senda Biosciences, Relation Therapeutics, Empress Therapeutics, IntrECate Biotherapeutics, and Dahlia Biosciences unrelated to this work. Received research support from Merck, Novartis, Leo Pharma, Janssen, the Bill and Melinda Gates Foundation, the Moore Foundation, the Pew-Stewart Trust, Foundation MIT, the Chan Zuckerberg Initiative, it is made available under a CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2021.09.17.21263540; this version posted August 6, 2025. The copyright holder for this preprint Novo Nordisk and the FDA unrelated to this work. Co-inventor on a provisional patent application relating to methods of stratifying and treating IBD. US Patent US20240150453A1, JO compensation for consulting services with Cellarity and Tessel Biosciences. Co-inventor on a provisional patent application relating to methods of stratifying and treating IBD. US Patent US20240150453A1, LK on the scientific advisory board for HiFiBio and Mammoth Biosciences. Research funding from Kymab Limited, Magenta Therapeutics, BlueBird Bio, and Regeneron Pharmaceuticals. Consulting fees from Equillium, Forty Seven Inc, Novartis Inc, EMD Serono, Gilead Sciences, Vertex Pharmaceuticals, and Takeda Pharmaceuticals. Grants and personal fees from Bristol Myers Squibb that are managed under an agreement with Harvard Medical School. Co-inventor on a provisional patent application relating to methods of stratifying and treating IBD. US Patent US20240150453A1
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests anti-TNF failure in Crohn's may be driven by pre-existing cytokine interaction networks and loss of regulatory feedback, which could help explain why some patients don't respond to TNF-blocking...
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
